

SAT KARTAR LIFE LIMITED

(Formerly known as Sat Kartar Shopping Limited)



Dated: 24.10.2026

To,
The Manager- Listing Compliance
National Stock Exchange India Limited
Exchange Plaza, Plot No. C/1, G Block,
Bandra Kurla complex, Bandra (E),
Mumbai 400051

SYMBOL: SATKARTAR
ISIN: INE0NB801022

Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 related to Press Release.

Dear Sir/Ma'am

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby enclose a press release issued by the Company highlighting its financial performance and financial results for the half year ended September 30, 2026.

You are requested to kindly take the above information, along with the enclosed press release, on record and acknowledge receipt of the same.

Thanking you,
Yours faithfully,
For Sat Kartar Life Limited
(Formerly known as Sat Kartar Shopping Limited)

Sonal
Seth

Sonal Seth
Company Secretary & Compliance Officer
Membership No. F13949
Date: 24.10.2026
Place: New Delhi

Digitally signed by Sonal Seth
DN: cn=Sonal Seth, o=Sat Kartar Life Limited,
ou=Listing Compliance, email=sonal.seth@satkartar.in,
c=IN, st=Delhi, serial=113949, version=1
Date: 2026.10.24 17:33:54 +05'30'

Regd Office: 603, 6th Floor, Mercantile House, KG Marg, New Delhi -110001
Tel No. +011-40550741, website: www.satkartar.in, Email id: info@satkartar.in
CIN: L52590DL2012PLC238241



Sat Kartar Life Limited

Sat Kartar Life Reports 26% Revenue Growth; 48% EBITDA Growth in H1 FY27

Company's First Ayurveda Hospital Turns Operating Breakeven

New Delhi, 24th October 2026 – **Sat Kartar Life Limited** (NSE: SATKARTAR), a technology-enabled Ayurveda healthcare company operating across Ayurvedic products and hospital-based care, announced its unaudited financial results for the half year ended 30th September 2026.

Key Financial Highlights

Particulars (₹ Crs)	H1 FY27	H1 FY26	Y-o-Y	H2 FY26	H-o-H
Revenue from Operations	113.9	90.1	26.4%	110.6	2.9%
Gross Profit	105.1	84.7	24.2%	101.6	3.5%
Gross Margin (%)	92.3%	94.0%	-170 bps	91.8%	50 bps
EBITDA	14.5	9.8	47.7%	14.9	-2.4%
EBITDA Margin (%)	12.7%	10.9%	180 bps	13.4%	-70 bps
Profit After Tax	9.2	7.3	26.7%	9.8	-5.6%
PAT Margin (%)	8.1%	8.1%	0 bps	8.9%	-80 bps
EPS (₹)	5.88	4.64		6.22	

Operational Highlights

30 Beds

Ayurveda hospital operational in Delhi

Breakeven

Hospital achieved on Sep 2026

160+ SKUs

1,600+

Workforce engaging in 7 languages

12,000+

Pincodes served across India

Strategic & Business Highlights

- **Healthcare Services Turn Breakeven:** The Company's first 30-bed Ayurveda hospital in Delhi achieved operational breakeven on September 2026, based on hospital-level operating performance, marking an important milestone in the Company's healthcare expansion strategy.
- **Insurance Coverage:** Entered into a common empanelment agreement with the General Insurance Council, covering 32 general and standalone health insurers. Eligible insured patients can avail insurance coverage for their treatment, supporting higher bed occupancy.
- **Hospital Network Expansion:** The Company announced a 10-15 bed hospital-cum-therapy centre in Gurugram (approx. ₹1 Cr investment) and signed a Letter of Intent for a 20-bed centre in Dehradun (approx. ₹70 lakh investment, targeted to be operational by 15th December 2026). Both are funded from IPO proceeds. Data-led site selection supports a rollout pace of ~3-5 hospitals per month at ~10-30 beds per facility.
- **Strengthened Capital Base:** Strengthened the Company's capital base through equity issuance and preferential warrants, with participation from investors and promoter commitment, supporting its future growth strategy.
- **US Market Entry:** Launched Shilajit Capsules, Shilajit Honey Sticks and Shilajit Resin for the US export market, marking the Company's first step into global, high-margin nutraceuticals.
- **Quality & Global Visibility:** Registered under the AYUSH Quality Mark initiative with AYUSHEXCIL and registered on the Heal in India platform, enhancing credibility and visibility among international patients seeking AYUSH healthcare.



Sat Kartar Life Limited

Commenting on the performance, Mr. Manprit Singh Chadha, Founder and Chief Operating Officer, Sat Kartar Life Limited, said,

"H1 FY27 marks a defining step in our transition from an Ayurvedic products company to an integrated Ayurveda healthcare enterprise. Our first hospital reached breakeven within about six months of commencing operations, and with insurance coverage across 32 insurers now in place, we are confident in the model as we replicate it in Gurugram, Dehradun and beyond.

Our products business continues to anchor growth, and with the launch of our Shilajit range in the US, we have taken our first step into global markets, opening a new, high-margin growth avenue.

Backed by a net-cash balance sheet and the continued commitment of our promoters, we are well positioned to build a scalable, integrated Ayurveda-led healthcare platform."

About Sat Kartar Life Limited

Founded in 2012, Sat Kartar Life Limited (NSE: SATKARTAR) is a technology-enabled Ayurveda healthcare company offering therapeutic and lifestyle solutions across products and clinical care. The Company offers 160+ doctor-formulated products manufactured in GMP and ISO certified facilities, addressing chronic and lifestyle conditions such as diabetes, joint care, liver health and de-addiction. Its digital-first, direct-to-consumer model serves customers across 12,000+ pincodes through a multilingual engagement platform.

In 2026, the Company expanded into healthcare delivery with its first 30-bed Ayurveda hospital in Delhi and is scaling an asset-light hospital network, building an integrated product-to-patient Ayurveda ecosystem. The Company has been listed on NSE Emerge since January 2025.

Safe Harbour Statement

Certain statements in this release concerning the Company's future growth prospects are forward-looking statements, which are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. These include, among others, competition, changes in consumer preferences, regulatory developments in the AYUSH and healthcare sectors, the Company's ability to execute its hospital expansion plans, economic conditions in India and overseas markets, and other factors beyond the Company's control. The Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date hereof.

Sat Kartar Life Limited	Investor Relations: X-B4 Advisory LLP
	
CIN: L52590DL2012PLC238241	Name: Gautam Kothari / Gautam Sipani
Email: info@satkartar.in	Email: gautam@x-b4.com / gautamsipani@x-b4.com
Tel: +91-11-40550741	Mobile: +91 79776 16640 / +91 90821 98752
Website: www.satkartar.in	Website: www.x-b4.com